Oncopeptides AB (publ) (ONCO.ST)
SEK 1.95
(-0.2%)
SEK 1.95
(-0.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 106.48 Million SEK | 2905.56% |
| 2022 | 3.54 Million SEK | 10.51% |
| 2021 | 3.2 Million SEK | -53.73% |
| 2020 | 6.92 Million SEK | -15.94% |
| 2019 | 8.24 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 114.88 Million SEK | 1.09% |
| 2024 Q1 | 113.64 Million SEK | 6.72% |
| 2023 Q2 | 109.17 Million SEK | 2373.36% |
| 2023 Q3 | 107.97 Million SEK | -1.09% |
| 2023 Q4 | 106.48 Million SEK | -1.38% |
| 2023 Q1 | 4.41 Million SEK | 24.58% |
| 2023 FY | 106.48 Million SEK | 2905.56% |
| 2022 Q3 | 5.89 Million SEK | -8.92% |
| 2022 Q1 | 6.35 Million SEK | 98.16% |
| 2022 Q2 | 6.46 Million SEK | 1.79% |
| 2022 FY | 3.54 Million SEK | 10.51% |
| 2022 Q4 | 3.54 Million SEK | -39.85% |
| 2021 FY | 3.2 Million SEK | -53.73% |
| 2021 Q4 | 3.2 Million SEK | 1578.53% |
| 2021 Q3 | 191 Thousand SEK | -84.94% |
| 2021 Q2 | 1.26 Million SEK | -64.47% |
| 2021 Q1 | 3.56 Million SEK | -48.49% |
| 2020 Q2 | 12.77 Million SEK | 12.89% |
| 2020 Q4 | 6.92 Million SEK | -29.94% |
| 2020 Q3 | 9.89 Million SEK | -22.59% |
| 2020 Q1 | 11.31 Million SEK | 37.29% |
| 2020 FY | 6.92 Million SEK | -15.94% |
| 2019 Q1 | 5.08 Million SEK | 0.0% |
| 2019 Q3 | 3.12 Million SEK | -23.92% |
| 2019 Q4 | 8.24 Million SEK | 164.2% |
| 2019 FY | 8.24 Million SEK | 0.0% |
| 2019 Q2 | 4.1 Million SEK | -19.3% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alzinova AB (publ) | 800 Thousand SEK | -13210.875% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -10548.7% |
| BioArctic AB (publ) | 2.15 Million SEK | -4848.281% |
| Calliditas Therapeutics AB (publ) | 939.5 Million SEK | 88.666% |
| Genovis AB (publ.) | 74.8 Million SEK | -42.347% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -226.828% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -63.228% |
| Simris Alg AB (publ) | 90.74 Million SEK | -17.354% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -3449.567% |
| Camurus AB (publ) | 13.61 Million SEK | -682.245% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 850 Thousand SEK | -12427.882% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -5946.962% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 112.89 Million SEK | 5.678% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Ziccum AB (publ) | 286 Thousand SEK | -37133.217% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -233.324% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -247.18% |
| Intervacc AB (publ) | 142 Thousand SEK | -74890.845% |
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -1316.804% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -334.446% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -2378.748% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -25014.858% |
| Egetis Therapeutics AB (publ) | 103.4 Million SEK | -2.985% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 844.9 Million SEK | 87.397% |
| Cyxone AB (publ) | 74 Thousand SEK | -143801.351% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -7315.529% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -78199.265% |
| SynAct Pharma AB | 58 Thousand SEK | -183498.276% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 14.53 Million SEK | -632.625% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -12427.882% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -60403.977% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |